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were significantly reduced in the ablation group compared to
controls (67% vs. 45%, respectively, at 24 months), but there
were no significant differences in mortality or quality of life.
The mean number of appropriate ICD shocks per patient per
year was 0.6 in the ablation group and a significantly higher
3.4 in controls.
Conclusions: RFCA of VT significantly reduces the incidence
of VT during follow-up in post-MI patients treated with an
ICD.
Perspective: In the OPTIC trial, amiodarone reduced ICD
shocks by 73%. Instead of prophylactic RFCA of VT in all
patients at the time of ICD implantation, one could make
the case for treatment with amiodarone, with RFCA being
reserved for patients who do not tolerate or who fail therapy
with amiodarone.  
Summary written by: Fred Morady, MD
Improved Survival Among Patients With
Eisenmenger Syndrome Receiving Advanced
Therapy for Pulmonary Arterial Hypertension
Dimopoulos K, Inuzuka R, Goletto S, et al.
Circulation 2010;121:20–25.
Study Question: Advanced therapy (AT) for pulmonary arte-
rial hypertension (PAH) in the context of congenital heart
disease improves pulmonary hemodynamics, functional class,
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Arrhythmias
Catheter Ablation of Stable Ventricular
Tachycardia Before Defibrillator Implantation in
Patients With Coronary Heart Disease (VTACH): 
A Multicentre Randomised Controlled Trial
Kuck KH, Schaumann A, Eckardt L, et al., on behalf of the VTACH Study
Group.
Lancet 2010;375:31–40.
Study Question: What is the clinical value of prophylactic
radiofrequency catheter ablation (RFCA) of ventricular
tachycardia (VT) before implantation of an implantable car-
dioverter/defibrillator (ICD)?
Methods: One hundred seven patients (mean age 66 years)
with stable VT, prior myocardial infarction (MI), and an
ejection fraction ≤50% (mean 34%) were randomly assigned
to undergo RFCA plus ICD implantation (n = 52) or only
ICD implantation (n = 55). Stored electrograms were ana-
lyzed to identify VT events during follow-up. Quality of life
was measured at each clinic visit.
Results: Approximately 30% of patients in both groups
received amiodarone during the mean follow-up of 22
months. The first episode of VT occurred at a median follow-
up of 18.6 months in the ablation group, compared to only
5.9 months in the control group. Cardiac hospitalizations
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monotherapy for hypertension. There were 4,661 patients
who developed AF during follow-up and 18,642 matched
control subjects who did not. Approximately 70% of patients
in both groups were at least 70 years old. The class of drug
used was analyzed in both groups.
Results: Compared to patients whose hypertension was
treated with a calcium-channel blocker (CCB), recipients of
an angiotension-converting enzyme inhibitor (ACEI) had a
25% lower risk of developing AF, recipients of an angioten-
sion II-receptor blocker (ARB) had a 29% lower risk, and
recipients of a beta-blocker had a 22% lower risk.
Conclusions: Treatment of hypertension with an ACEI,
ARB, or beta-blocker reduces the risk of new-onset AF
compared to CCBs.
Perspective: Several studies have demonstrated that ACEIs and
ARBs reduce the risk of AF. Possible mechanisms include
lowering of blood pressure, prevention or treatment of heart
failure, and prevention of atrial fibrosis. CCBs lower the
blood pressure, but do not prevent heart failure or atrial fibro-
sis. Therefore, the results of this study suggest that prevention
of heart failure and/or atrial fibrosis explain the lower risk of
AF when hypertension is treated with an ACEI, ARB, or
beta-blockers.  
Summary written by: Fred Morady, MD 
Congenital Heart Disease
Aortic Elasticity and Size Are Associated With
Aortic Regurgitation and Left Ventricular
Dysfunction in Tetralogy of Fallot After Pulmonary
Valve Replacement
Grotenhuis HB, Ottenkamp J, de Bruijn L, et al.
Heart 2009;95:1931–1936.
Study Question: What are the relationships between aortic
elasticity, aortic valve competence, and biventricular function
in patients with repaired tetralogy of Fallot (TOF) who have
undergone pulmonary valve replacement?
Methods: A prospective case-controlled study was performed.
Sixteen patients with TOF and 16 age- and gender-matched
controls underwent cardiac magnetic resonance imaging for
evaluation of aortic root dimensions, biventricular function,
aortic elasticity, and quantification of aortic regurgitation.
Results: Aortic root dimensions at the sinuses of Valsalva
were larger in the TOF patients (39.3 ± 5.4) compared with
and the 6-minute walk test. Has AT affected survival in the
Eisenmenger syndrome?
Methods: Data on all Eisenmenger patients attending a single
center over the past decade were collected. Survival rates
were compared between patients on and off AT with the
use of a modified version of the Cox model, which treats
modern AT as a time-varying covariate. Baseline differences
were adjusted for the use of propensity scores.
Results: A total of 229 patients (ages 34.5 ± 12.6 years; 35.4%
male) were included. The majority had complex anatomy,
and 53.7% were in New York Heart Association (NYHA)
class ≥III at baseline. Sixty-eight patients (29.7%) either were
on AT or had AT initiated during follow-up. During a
median follow-up of 4.0 years, 52 patients died, only 2 of
them while on AT. Patients on AT were at a significantly
lower risk of death, both unadjusted and after adjustment for
baseline clinical differences by propensity score regression
adjustment (C statistic = 0.80; hazard ratio, 0.16; p = 0.015)
and propensity score matching (hazard ratio, 0.10; p = 0.028).
Despite being older and sicker, only 2 of the 68 patients who
received AT for a median period of 2.4 years died, compared
with 50 deaths in those not receiving AT.
Conclusions: Advanced treatment for PAH in adults with
Eisenmenger syndrome was associated with a lower risk of
death. Survival benefits should be considered together with
improved hemodynamics and functional class when deci-
sions are made about their treatment.
Perspective: The prostanoids, endothelin antagonists, and
phosphodiesterase-5 inhibitors (ATs) have been effective at
improving quality of life in PAH. The survival advantage of
those treated with AT in this single center as measured by
the hazard ratio is over ninefold, despite the fact that
patients receiving the novel drugs were more often NYHA
class IV, older, and had more syncope.  
Summary written by: Melvyn Rubenfire, MD
Risk for Incident Atrial Fibrillation in Patients Who
Receive Antihypertensive Drugs: A Nested Case-
Control Study
Schaer BA, Schneider C, Jick SS, Conen D, Osswald S, Meier CR.
Ann Intern Med 2010;152:78–84.
Study Question: Is the risk of developing atrial fibrillation (AF)
affected by the type of medication used to treat hypertension?
Methods: Subjects of this retrospective study were selected from
a primary-care database in the United Kingdom and received
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zation as well as in-hospital major bleeding events and death.
Results: Overall, 30.5% and 42.9% of patients with STEMI
and NSTEMI, respectively, had CKD. Regardless of MI
type, patients with progressively more severe CKD had
higher rates of death. For STEMI, the odds ratio for stage
3a, 3b, 4, and 5 CKD compared with patients with no
CKD was 2.49, 3.72, 4.82, and 7.97, respectively. For
NSTEMI, the analogous odds ratios were 1.81, 2.41, 3.50,
and 4.09. In addition, patients with progressively more
severe CKD were less likely to receive immediate evidence-
based therapies including aspirin, beta-blockers, or
clopidogrel, were less likely to undergo any reperfusion
(STEMI) or revascularization (NSTEMI), and had higher
rates of bleeding.
Conclusions: Patients with CKD still receive fewer evidence-
based therapies and have substantially higher mortality rates.
Perspective: Clinicians should be aware of the high likelihood
of concomitant CKD and cardiovascular disease in patients
presenting with MI to allow for appropriate treatment deci-
sions and to adjust medication dosing. The underutilization of
evidence-based therapies and procedures in the CKD popula-
tion is an important health care quality issue and an
opportunity to develop appropriate quality improvement ini-
tiatives to optimize care in these high-risk patients.  
Summary written by: Debabrata Mukherjee, MD 
A Sensitive Cardiac Troponin T Assay in Stable
Coronary Artery Disease
Omland T, de Lemos JA, Sabatine MS, et al., on behalf of the
Prevention of Events With Angiotensin Converting Enzyme Inhibition
(PEACE) Trial Investigators.
N Engl J Med 2009;361:2538–2547.
Study Question: What are the prognostic implications of ele-
vated troponin T levels in stable coronary artery disease
(CAD) patients?
Methods: A new highly sensitive troponin T assay was used
in 3,679 patients with stable CAD and preserved left ven-
tricular function. Patients were followed for an average of
5.2 years for cardiovascular (CV) events.
Results: Concentrations of cardiac troponin T were at or
above detection limit (0.001 μg/L) in 97.7% of patients (n =
3,593) and at or above the 99th percentile for apparently
healthy subjects (0.0133 μg/L) in 11.1% of patients (n =
407). After adjustment for other prognostic indicators, there
was a strong and graded increase in the cumulative inci-
the controls (30.4 ± 3.1). Reduced aortic elasticity was also
seen in the TOF group (pulse wave velocity in the aortic
arch of 5.5 ± 1.2 m/s compared with 4.6 ± 0.9 m/s). TOF
patients were also found to have increased aortic regurgita-
tion (regurgitant fraction of 6% vs. 1%, p < 0.01) and
decreased left ventricular ejection fraction (LVEF) (51% vs.
58%, p = 0.01), whereas right ventricular ejection fraction
(RVEF) was preserved in both groups.
Conclusions: Aortic root dilatation and reduced aortic elastic-
ity are frequently seen in patients following repair of TOF
and pulmonary valve replacement. Aortic wall pathology
may contribute to LV dysfunction in this patient population.
Perspective: LV dysfunction has been well-documented in
patients after TOF repair, and has often been attributed to
intraventricular dependence, as well as perioperative insults
with early bypass techniques. This study shows a relationship
between relatively mild degrees of aortic insufficiency and root
dilatation with LV dysfunction. This study emphasizes the
complexity of etiologies contributing to LV dysfunction in
patients following repair of TOF.  
Summary written by: Timothy B. Cotts, MD
General Cardiology
Use of Evidence-Based Therapies in Short-Term
Outcomes of ST-Segment Elevation Myocardial
Infarction and Non–ST-Segment Elevation
Myocardial Infarction in Patients With Chronic
Kidney Disease. A Report From the National
Cardiovascular Data Acute Coronary Treatment
and Intervention Outcomes Network Registry
Fox CS, Muntner P, Chen AY, et al.
Circulation 2010;121:357–365.
Study Question: What is the association between chronic kid-
ney disease (CKD) severity and short-term outcomes and
the use of in-hospital evidence-based therapies among
patients with ST-segment elevation myocardial infarction
(STEMI) and non–STEMI (NSTEMI)?
Methods: The study sample was drawn from the Acute
Coronary Treatment and Intervention Outcomes Network
registry, a nationwide sample of STEMI (n = 19,029) and
NSTEMI (n = 30,462) patients. Estimated glomerular filtra-
tion rate was calculated with the Modification of Diet in
Renal Disease equation in relation to use of immediate (first
24 hours) therapies and early (first 48 hours) cardiac catheteri-
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dence of CV death (hazard ratio [HR] per unit increase in
natural log of troponin T level, 2.09; 95% confidence inter-
val [CI], 1.60-2.74; p < 0.001) and of heart failure (HR,
2.20; 95% CI, 1.66-2.90; p < 0.001). Increased risk with
higher troponin T levels was evident well below the limit of
detection of conventional cardiac troponin T assays and
below the 99th percentile of values in a healthy population.
There was no association between troponin T levels, as
measured with this assay, and incidence of myocardial
infarction (MI).
Conclusions: After adjustment for other prognostic indicators,
cardiac troponin T levels, as measured with a highly sensi-
tive assay, were significantly associated with incidence of
CV death and congestive heart failure, but not with MI in
patients with stable CAD.
Perspective: With development of a highly sensitive troponin
T assay, the authors have demonstrated that low troponin T
levels may be useful in predicting some adverse CV out-
comes, independent of conventional risk factors. Several
questions are raised including the cellular source and mecha-
nism of low level troponin generation, which may provide
guidance to the appropriate management of these patients.
The clinical utility of this sensitive screening assay will
require additional studies.  
Summary written by: Daniel T. Eitzman, MD
Strength of Study Evidence Examined by the FDA
in Premarket Approval of Cardiovascular Devices
Dhruva SS, Bero LA, Redberg RF.
JAMA 2009;302:2679–2685.
Study Question: What is the type and strength of evidence on
which premarket approval (PMA)—the most stringent
Food and Drug Administration (FDA) review process is
based?
Methods: This was a systematic review of 123 summaries of
safety and effectiveness data for 78 PMAs for high-risk car-
diovascular devices that received PMA between January
2000 and December 2007. Examination of the methodolog-
ical characteristics considered essential to minimize
confounding and bias, as well as the primary endpoints of
the 123 studies supporting the PMAs, was performed.
Results: Thirty-three of 123 studies (27%) used to support
recent FDA approval of cardiovascular devices were random-
ized and 17 of 123 (14%) were blinded. Fifty-one of 78
PMAs (65%) were based on a single study. One hundred
eleven of 213 primary endpoints (52%) were compared with
controls and 34 of 111 controls (31%) were retrospective. One
hundred eighty-seven of 213 primary endpoints (88%) were
surrogate measures and 122 of 157 (78%) had a discrepancy
between the number of patients enrolled in the study and the
number analyzed.
Conclusions: PMA of cardiovascular devices by the FDA is
often based on studies that lack adequate strength and may
be prone to bias.
Perspective: The FDA approval process is an important
determinant of health care spending, and spending on new
devices increases when the FDA approves devices more
quickly. Cost containment would likely occur if rigorous
clinical effectiveness reviews were used for new drugs, tech-
nologies, and devices shown to benefit patients definitively.
The emphasis of FDA in the future should be research that
meets rigorous scientific standards for evidence of benefit
and lack of harm to patients.  
Summary written by: Debabrata Mukherjee, MD
Recommendations for Interpretation of 12-Lead
Electrocardiogram in the Athlete 
Corrado D, Pelliccia A, Heidlbuchel H, et al.
Eur Heart J 2009;Dec 22:[Epub ahead of print]. 
Perspective: The following are 10 points to remember from
this position paper formulated by the European Society of
Cardiology:
1: Electrocardiographic findings that are common, training-
related, and do not require additional evaluation are sinus
bradycardia, 1° atrioventricular block (AVB), incomplete
right bundle branch block (BBB), early repolarization, and
isolated voltage criteria for left ventricular hypertrophy
(LVH). 
2: Uncommon and training unrelated electrocardiographic
findings that mandate further evaluation include T-wave
inversion, ST-segment depression, pathological Q waves,
atrial enlargement, a hemiblock, right ventricular hypertro-
phy, a BBB, or a Brugada-pattern of ST-segment elevation.
3: Training-related electrocardiographic findings are more
common in men than women, athletes of African descent,
and high-endurance athletes such as cyclists.
4: Sinus rates <30 bpm and sinus pauses >2 seconds are
common in highly trained athletes, particularly during sleep.  
5: The routine use in all patients of perioperative beta-adren-
ergic antagonists does not reduce perioperative adverse events.
6: Data support a strategy of beta-blocker therapy, titrated
to hemodynamic variables, in high-risk patients with
ischemic heart disease who are undergoing high-risk sur-
gery.
7: The implementation of an evidence-based doctrine of selec-
tive beta-blocker therapy among high-risk patients with
ischemic heart disease undergoing high-risk surgery, selective
preoperative functional testing only to identify those high-risk
patients, and preoperative coronary revascularization only in
very selected cases, is not necessarily the current standard of
practice.
8: At the authors’ institution, two educational initiatives sup-
porting the ACC/AHA perioperative guideline recommen-
dations resulted in lower costs for preoperative risk assess-
ment, but preserved or improved perioperative patient
outcomes.
Summary written by: David S. Bach, MD
Systematic Review: Prediction of Perioperative
Cardiac Complications and Mortality by the
Revised Cardiac Risk Index
Ford MK, Beattie WS, Wijeysundera DN.
Ann Intern Med 2010;152:26–35.
Study Question: What is the ability of the Revised Cardiac Risk
Index (RCRI) to predict cardiac complications and death
after noncardiac surgery?
Methods: MEDLINE, EMBASE, and ISI Web of Science
(1966 to December 31, 2008) were searched for cohort
studies that reported the association of the RCRI with
major cardiac complications (cardiac death, myocardial
infarction, and nonfatal cardiac arrest) or death (in-hospital
or within 30 days of surgery). Two reviewers independently
extracted study characteristics, documented outcome data,
and evaluated study quality.
Results: Of 24 studies (including 792,740 patients), 18 stud-
ies reported cardiac complications; 6 of the 18 studies were
prospective and had uniform outcome surveillance and
blinded outcome adjudication. The RCRI discriminated
moderately well between patients at low versus high risk for
cardiac events after mixed noncardiac surgery (area under
the receiver-operating characteristic curve [AUC] 0.75, sen-
sitivity 0.65, specificity 0.76, positive likelihood ratio 2.78,
5: A normal chronotropic response to exertion and absence of
bradycardia-related symptoms distinguishes training-related
sinus bradycardia from sinus node dysfunction.
6: 1° AVB and Mobitz I 2° AVB are common, but Mobitz
II 2° AVB or 3° AVB should not be assumed to be train-
ing-related and require evaluation.
7: Early repolarization in Caucasian athletes commonly con-
sists of upwardly concave ST-segments and tall and peaked T
waves; in black athletes, there often is convex ST-segment ele-
vation and negative T waves, mimicking a Brugada pattern.
8: In the presence of voltage criteria for LVH, pathological
hypertrophy should be suspected if there is left atrial enlarge-
ment, left-axis deviation, repolarization abnormalities, or
pathological Q waves.
9: T-wave inversion ≥2 mm in ≥2 adjacent leads should
prompt evaluation for structural heart disease.
10: Electrophysiological testing for risk stratification with pos-
sible catheter ablation is appropriate in athletes with
ventricular pre-excitation.
Summary written by: Fred Morady, MD
Perioperative Practice: Time to Throttle Back 
Chopra V, Flanders SA, Froehlich JB, Lau WC, Eagle KA.
Ann Intern Med 2010;152:47–51.
Perspective: This perspective discusses how the current prac-
tice of perioperative risk assessment often conflicts with
trial-based evidence; and advocates that, by heeding existing
evidence and implementing the American College of
Cardiology (ACC)/American Heart Association (AHA)
guidelines, perioperative costs can be reduced while out-
comes are improved. The following are points to remember.
1: Screening stable patients for coronary artery disease
(CAD) before noncardiac surgery does not improve periop-
erative outcomes. 
2: The preoperative identification of significant CAD does
not necessarily lead to the identification of patients at
increased perioperative cardiac risk.
3: Preoperative coronary revascularization does not lower
perioperative cardiac risk.
4: Failure of a strategy to reduce risk using preoperative
coronary revascularization might fail for several reasons.  
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negative likelihood ratio 0.45). Prediction of cardiac events
after vascular noncardiac surgery was less accurate (AUC
0.64, sensitivity 0.70, specificity 0.55, positive likelihood
ratio 1.56, negative likelihood ratio 0.55). Six studies
reported death, with a median AUC of 0.62. A pooled
AUC for predicting death could not be calculated because of
very high heterogeneity.
Conclusions: RCRI discriminated moderately well between
patients at low versus high risk for cardiac events after
mixed noncardiac surgery. However, it did not perform well
at predicting death or cardiac events after vascular noncar-
diac surgery.
Perspective: The RCRI is a multivariable index that uses
readily available clinical information in an attempt to predict
perioperative risk. In its original single-institutional cohort
of ~3,000 patients undergoing noncardiac surgery, the
model had good discriminatory power. However, the pres-
ent study shows that the same index was more limited when
tested in different patient populations in varying geographic
locations. Importantly, retrospective correlation, even among
prospectively collected data, does not prove that a model will
be predictive in other populations; the present study proved
just that.  
Summary written by: David S. Bach, MD
Heart Failure/Transplant
Cardio-Renal Syndromes: Report From the
Consensus Conference of the Acute Dialysis
Quality Initiative
Ronco C, McCullough P, Anker SD, et al.
Eur Heart J 2009;Dec 25:[Epub ahead of print]. 
Perspective: The following are 10 points to remember about
cardio-renal syndromes.
1: The Consensus Conference on Cardio-Renal Syndromes
identified five subtypes that have different pathophysiology
(refer to Figures 1-5 in J Am Coll Cardiol 2008;52:1527-39),
prevention, and management strategies (Table 1).
2: Type 1 or acute cardio-renal syndrome: acute worsening of
heart function leading to kidney injury and/or dysfunction.
3: Type 2 or chronic cardio-renal syndrome: chronic abnor-
malities in heart function leading to kidney injury or
dysfunction.
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4: Type 3 or acute reno-cardiac syndrome: acute worsening of
kidney function leading to heart injury and/or dysfunction.  
5: Type 4 or chronic reno-cardiac syndrome: chronic kidney
disease leading to heart injury, disease, and/or dysfunction.
6: Type 5 or secondary cardio-renal syndrome: systemic
conditions leading to injury and/or dysfunction of both
heart and kidney.
7: B-type natriuretic peptide (BNP) and NT-BNP may be ele-
vated in cardio-renal syndrome types 1, 2, and 4.
8: Neutrophil gelatinase-associated lipocalin of urine and
plasma and cystatin C are two biomarkers of renal injury that
are most likely to be integrated in clinical practice and help
with management of cardio-renal syndrome.
9: Bioimpedance vector analysis may contribute to better
definition of the patient’s hydration status.
10: The presence of coronary artery disease should be excluded
by stress echo or stress myocardial perfusion in types III, IV,
and V and in types I and II cardio-renal syndrome when the
primary disease is valvular, congenital, or myopathic to avoid
contrast-induced renal damage.
Summary written by: Ragavendra R. Baliga, M.B.B.S.
Noninvasive Cardiology
ST Elevation on the Exercise ECG in Patients
Presenting With Chest Pain and No Prior History
of Myocardial Infarction
Murphy JC, Scott PJ, Shannon HJ, et al.
Heart 2009;95:1792–1797. 
Study Question: What is the etiology of ST-segment elevation
(STE) noted during exercise stress testing (EST) in patients
with chest pain, but without a prior history of myocardial
infarction (MI)?
Methods: Stress testing with ECG monitoring was undertaken
in 19,189 patients over an 8-year period. EST was performed
with a standard Bruce protocol, and beta-blockers were held
prior to testing. There was evidence of prior MI in 4,248,
leaving 14,941 EST for evaluation. Within this cohort, 116
(0.78%) patients had STE during or after exercise.
Results: All patients were Caucasian (average age 57 years,
79.3% male). Mean exercise duration was 6 minutes and mean
maximum predicted heart rate achieved was 86.7%. EST was
terminated for chest pain in 56 and STE in 39. STE first
occurred in both stage 1 and 2 in 30%, and was noted only in
recovery in 24.1%. Coronary arteriography was performed in
108/116 patients, and coronary stenosis >70% was noted in
all. Single-vessel disease was noted in 60 patients, 14 of whom
had occluded or subtotally occluded arteries. Anterior STE
was seen in 41 subjects, 40 of whom had severe disease in the
left anterior descending coronary artery, and inferior STE was
noted in 66, 63 of whom had either right or circumflex coro-
nary disease.
Conclusions: STE on exercise treadmill testing is a rare but
highly specific finding for severe coronary artery disease, and
the location of STE predicts the anatomical location of the
disease.
Perspective: In this Caucasian population, the incidence of
STE during or after exercise was low, but the finding was
highly specific for severe fixed obstructive coronary disease.
The location of STE was 95% predictive of the anatomical
disease location. Other studies with demographically differ-
ent patient populations have suggested that STE may be
more predictive of coronary vasospasm. STE on stress test-
ing should probably prompt further assessment with
coronary arteriography.  
Summary written by: William F. Armstrong, MD
Prevention/Vascular
Prevalence and Trends in Obesity Among US
Adults, 1999–2008
Flegal KM, Carroll MD, Ogden CL, Curtin LR.
JAMA 2010;Jan 13:[Epub ahead of print].
Study Question: Has there been a change in the trend for
increasing prevalence of obesity and overweight from 1999
through 2008?
Methods: The results are based on the analysis of height and
weight measurements from 5,555 adult men and women ages
20 years or older obtained in 2007-2008 as part of the
National Health and Nutrition Examination Survey
(NHANES). Data from NHANES were compared with
results obtained from 1999 through 2006. Overweight was
defined as a body mass index (BMI) of 25.0-29.9 kg/m2 and
obesity as a BMI of 30.0 kg/m2 or higher.
Results: In 2007-2008, the age-adjusted prevalence of obesity
was 33.8% overall, 32.2% among men, and 35.5% among
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women. The prevalence estimates for overweight and obe-
sity combined were 68.0%, 72.3%, and 64.1%. Obesity
prevalence varied by age group and by racial and ethnic
group for both men and women. Over the 10-year period,
obesity showed no significant trend among women (adjusted
odds ratio [AOR] for 2007-2008 vs. 1999-2000, 1.12 [95%
CI, 0.89-1.32]). For men, there was a significant linear
trend (AOR for 2007-2008 vs. 1999-2000, 1.32 [95% CI,
1.12-1.58]); however, the three most recent data points did
not differ significantly from each other.
Conclusions: The increase in prevalence of obesity previously
observed does not appear to be continuing at the same rate
over the past 10 years, particularly for women and possibly
for men.
Perspective: That the trend for increasing obesity appears to
have stopped is not much of an accomplishment. The US
population-based efforts to impact the prevalence of obesity
from 1999-2008 by education have been impressive, but the
results are disappointing. In 2007-2008, nearly 20% of men
and women had a BMI >35 kg/m2, which underscores the
need for novel and safe drugs for targeting weight loss.  
Summary written by: Melvyn Rubenfire, MD 
Two Self-Management Interventions to Improve
Hypertension Control: A Randomized Trial
Bosworth HB, Olsen MK, Grubber JM, et al.
Ann Intern Med 2009;151:687–695.
Study Question: What is the effectiveness of blood pressure
(BP) self-management, or a tailored, nurse-administered
health behavior intervention, or both, in the improvement
of BP?
Methods: This was a 2 x 2 randomized trial, stratified by
enrollment site and patient health literacy status, to either
usual care, versus home BP monitoring thrice weekly, versus a
tailored behavioral telephone intervention, versus behavioral
intervention plus BP monitoring. Primary outcome was BP
control at 6-month intervals over 24 months.
Results: Of 636 hypertensive patients, 475 (75%) completed
the 24-month follow-up. The proportion of patients with
controlled BP beyond that seen with usual care was 4.3% in
the behavioral intervention group, 7.6% in the home BP
monitoring group, and 11.0% in the combined intervention
group. Relative to the usual care group, the change in sys-
tolic BP was 0.6 mm Hg for the behavioral group, -0.6 mm
Hg for the BP monitoring group, and -3.9 mm Hg for the
combined intervention group. Similar findings occurred for
diastolic BP.
Conclusions: Combined home BP monitoring and tailored
behavioral telephone intervention improved both systolic and
diastolic BP control at 24 months, compared with usual care.
Perspective: This study showed a trend toward improvement
in BP with each intervention, but suggests that the only sig-
nificant improvement came with using both home BP
monitoring and the behavioral intervention. Programs based
on this type of intervention could have great health and cost
benefits, if we could design a health care system with the
capacity to efficiently provide this type of support.  
Summary written by: James B. Froehlich, MD 
Prevalence of High Body Mass Index in US
Children and Adolescents, 2007-2008
Ogden CL, Carroll MD, Curtin MM, Flegal KM.
JAMA 2010;303:242–249.
Study Question: What is the prevalence of high body mass index
(BMI) among children and adolescents in the United States?
Methods: Using data from the National Health and Nutrition
Examination Survey, 2007-2008, BMI was estimated for
3,281 children (ages 2-19 years) and 719 infants and toddlers.
Prevalence of high weight for recumbent length (≥95th per-
centile) was calculated from 1999 to 2008. Prevalence of high
BMI was calculated for children and adolescents with high
BMI defined as three groups: BMI ≥97th percentile, BMI
≥95th percentile, and BMI ≥85th percentile for age. Trends
over time were examined by age, sex, and race/ethnicity.
Results: The prevalence of high BMI in 2007-2008 was 9.5%
(95% confidence interval [CI], 7.3%-11.7%) for infants and
toddlers. For children and adolescents, the prevalence of those
at or above the 97th percentile for BMI was 11.9%, 16.9% for
BMI ≥95th percentile, and 31.7% for BMI ≥85th percentile.
No significant trends over time were observed between 1999-
2000 and 2007-2008, with the exception of boys, ages 6-19
years, with BMIs ≥97th percentile (odds ratio [OR], 1.52;
95% CI, 1.17-2.01) and for non-Hispanic white boys ages 6-
19 years (OR, 1.87; 95% CI, 1.22-2.94).
Conclusions: No significant linear trends were observed for high
BMI over the past 11 years, with the exception of boys in the
highest BMI category.
Perspective: These data suggest a leveling off of the prevalence
of overweight and obese children in the United States.
However, given the numbers of children with high BMI,
aggressive prevention of obesity among US children is still
warranted.  
Summary written by: Elizabeth A. Jackson, MD
Genetic Variants Associated With Lp(a)
Lipoprotein Level and Coronary Disease
Clarke R, Peden JF, Hopewell JC, et al., on behalf of the PROCARDIS
Consortium.
N Engl J Med 2009;36:2518–2528.
Study Question: What gene variants are associated with coro-
nary artery disease (CAD) and Lp(a) levels?
Methods: A gene chip was used containing 48,742 single-
nucleotide polymorphisms (SNPs) in 2,100 candidate genes
to test for associations in 3,145 case subjects with CAD and
3,352 control subjects. Replication testing was performed in
three independent populations involving 4,846 additional case
subjects with CAD and 4,594 control subjects.
Results: Three chromosomal regions (6q26-27, 9p21, and
1p13) were strongly associated with the risk of CAD. The
LPA locus on 6q26-27 encoding Lp(a) lipoprotein had the
strongest association. A common variant (rs10455872) was
identified at the LPA locus with an odds ratio for CAD of
1.70 and another independent variant (rs3798220) with an
odds ratio of 1.92. Both variants were strongly associated
with an increased level of Lp(a) lipoprotein, a reduced copy
number in LPA, and a small Lp(a) lipoprotein size.
Replication studies confirmed the effects of both variants on
Lp(a) lipoprotein level and the risk of CAD.
Conclusions: Two LPA variants identified were strongly associ-
ated with both an increased level of Lp(a) lipoprotein and an
increased risk of CAD. These findings support a casual role
of Lp(a) lipoprotein in CAD.
Perspective: Levels of Lp(a) are strongly heritable and the
current study elucidates important common genetic variants
of Lp(a) levels. Because these gene variants are also strongly
associated with CAD, these findings provide causal support
for a role of Lp(a) in CAD.  
Summary written by: Daniel T. Eitzman, MD
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